Research programme: CEL 1000 - CEL-SCI

Drug Profile

Research programme: CEL 1000 - CEL-SCI

Alternative Names: CEL 1000; CEL-1000 peptide; derG; DGQEEKAGVVSTGLIGGG

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CEL-SCI Corporation
  • Developer CEL-SCI Corporation; National Institute of Allergy and Infectious Diseases; Naval Medical Research Center; United States Army Medical Research Institute of Infectious Diseases; University of Arkansas System; University of Nebraska Medical Center
  • Class Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Encephalitis virus infections; Hepatitis B; Herpes simplex virus infections; Influenza A virus H5N1 subtype; Malaria; Severe acute respiratory syndrome; Smallpox; Vaccinia; West Nile virus infections
  • Discontinued Chlamydial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Encephalitis-virus-infections in USA (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in USA (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top